Cargando…
HFE hemochromatosis: an overview about therapeutic recommendations
Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885398/ https://www.ncbi.nlm.nih.gov/pubmed/34824033 http://dx.doi.org/10.1016/j.htct.2021.06.020 |
_version_ | 1784660410215956480 |
---|---|
author | Cancado, Rodolfo D. Alvarenga, Aline Morgan Santos, Paulo Caleb JL |
author_facet | Cancado, Rodolfo D. Alvarenga, Aline Morgan Santos, Paulo Caleb JL |
author_sort | Cancado, Rodolfo D. |
collection | PubMed |
description | Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other iron overload diseases or conditions which can lead to this phenotype. In the present review, the main aims are to show updates on hemochromatosis and to report a practical set of therapeutic recommendations for the human factors engineering protein (HFE) hemochromatosis for the p.Cys282Tyr (C282Y/C282Y) homozygous genotype, elaborated by the Haemochromatosis International Taskforce. |
format | Online Article Text |
id | pubmed-8885398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sociedade Brasileira de Hematologia e Hemoterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-88853982022-03-04 HFE hemochromatosis: an overview about therapeutic recommendations Cancado, Rodolfo D. Alvarenga, Aline Morgan Santos, Paulo Caleb JL Hematol Transfus Cell Ther Special Article Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other iron overload diseases or conditions which can lead to this phenotype. In the present review, the main aims are to show updates on hemochromatosis and to report a practical set of therapeutic recommendations for the human factors engineering protein (HFE) hemochromatosis for the p.Cys282Tyr (C282Y/C282Y) homozygous genotype, elaborated by the Haemochromatosis International Taskforce. Sociedade Brasileira de Hematologia e Hemoterapia 2022 2021-11-17 /pmc/articles/PMC8885398/ /pubmed/34824033 http://dx.doi.org/10.1016/j.htct.2021.06.020 Text en © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Special Article Cancado, Rodolfo D. Alvarenga, Aline Morgan Santos, Paulo Caleb JL HFE hemochromatosis: an overview about therapeutic recommendations |
title | HFE hemochromatosis: an overview about therapeutic recommendations |
title_full | HFE hemochromatosis: an overview about therapeutic recommendations |
title_fullStr | HFE hemochromatosis: an overview about therapeutic recommendations |
title_full_unstemmed | HFE hemochromatosis: an overview about therapeutic recommendations |
title_short | HFE hemochromatosis: an overview about therapeutic recommendations |
title_sort | hfe hemochromatosis: an overview about therapeutic recommendations |
topic | Special Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885398/ https://www.ncbi.nlm.nih.gov/pubmed/34824033 http://dx.doi.org/10.1016/j.htct.2021.06.020 |
work_keys_str_mv | AT cancadorodolfod hfehemochromatosisanoverviewabouttherapeuticrecommendations AT alvarengaalinemorgan hfehemochromatosisanoverviewabouttherapeuticrecommendations AT santospaulocalebjl hfehemochromatosisanoverviewabouttherapeuticrecommendations |